Cellectis S.a. · EURONEXT:ALCLS
Cellectis — Investor Day (June 2026)
65 slides from Cellectis's investor day presentation, June 2026
Slide 1: R&D Day: BALLI-01 Phase 1 & Phase 2 Strategy
R&D Day BALLI-01 Phase 1 & Phase 2 Strategy DRAFT
Slide 2: Forward Looking Statements
Forward-Looking Forward Looking Statements Statement This presentation contains “forward-looking” statements within These forward-looking statements are made in light of the meaning of applicable securities laws, including the Private information currently available to us and are subject to Securiti
Slide 3: Lasme-cel could be a game changer in refractory or relapsed B-ALL
Lasmecabtagene Timgedleucel or Lasme-cel (UCART22) Lasme-cel could be a game changer in refractory or relapsed B-ALL Lasme-cel is not FDA approved P3
Slide 4: Today's Reveal
Today’s Reveal 1. The BALLI-01 Study for Patients with r/r B-ALL • Phase 1 Update → Lessons Learned • Phase 2 Design → Path to BLA and Market Panel Discussion with Oncology Experts 2. Lasme-cel Market Opportunity • Patient Need & Addressable Market • Where We Create Value 4. Building Tomorrow’s Cell
Slide 5: B-ALL: An Unmet Medical Need
B-ALL: AnUnmet ALL: an UnmetMedical MedicalNeed Need B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA • 1L treated population: ~9,200 Patients (US, EU4, UK)* High relapse in adults HURDLES WITH EXISTING TREATMENTS • Chemotherapies: Lead to high relapse rate in adults • ADCs have a limited effect: Low antigen exp
Slide 6: Why an Allogeneic CD22 CAR-T Product for r/r B-ALL?
Why Whyan anAllogeneic AllogeneicCD22 CD22 CAR-T CAR-T cell product Product for forr/r r/rB-ALL? B-ALL? Allogeneic CAR-T Starts with Healthy-donor T Cells Healthier and less exhausted than autologous cells from heavily pretreated patients Off-the-Shelf is designed for “Speed” – in B-ALL Every Day Co
Slide 7: Fully Integrated Manufacturing
Fully Fully Integrated Manufacturing Integrated Manufacturing Paris, France Raleigh, NC CMC Development, UCART – Clinical & Intended Starting Materials Commercial Ready Site 14,000 sq ft. facility 82,000 sq ft. facility Allogeneic CAR-T ✓ Process & analytical development ✓ UCART GMP manufacturing ✓
Slide 8: Lasme-cel as Bridge to Transplant Strategy
Lasme-cel as Lasme-cel as Bridge Bridge to Transplant TransplantStrategy Strategy HSCT as the Gold Standard For r/r B-ALL THE GOAL Achieve a Path to a Potentially Curative HSCT ➢ Secure a remission window ➢ Make patient eligible for an HSCT ➢ Clear path to long-term remission ➢ Manageable safety pro
Slide 9: BALLI-01 Phase 1 Data Review & Design of Pivotal Phase 2
R&D Day BALLI-01 Phase 1 Data Review & Design of Pivotal Phase 2 DRAFT
Slide 10: Eti-cel (UCART20x22): High Response Rates in R/R NHL
Eti-cel (UCART20x22): High Response Rates in R/R NHL Response rate (%) [n=7] 100 90 80 Percentage (%) 70 4/7 CR at 60 Current 50 86% Dose 57% 40 30 Level 20 10 0 ORR CR Update on Program at the End of the Year 2025 ORR: overall response rate; CR: complete response ; r/r NHL: Relapsed or refractory n
Slide 11: B-ALL: Chemo and Targeted Therapies Lead, Transplant Is the Cure
B-ALL: Chemo and Targeted Therapies Lead, Transplant Is the Cure ALL Treatment Paradigm Frontline Induction: Chemo (± TKI1) All patients Consolidation: Chemo ± TKI (MRD-) Blincyto (MRD+) 2nd Line (R/R) Chemo Auto CD19 Blincyto Besponsa (± TKI) CAR-T 3rd Line (R/R) Auto CD19 Other (i.e., Chemo, Clini
Slide 12: Poor Response Rates after Targeted Therapy Failure
Poor Response Rates after Targeted Therapy Failure 1 After targeted therapy failure, salvage chemo yields low ODD and MRD 2: High unmet need in heavily Post Blina failure Post Ino failure Post CAR-T failure pretreated patients ORR <20% ORR <10-15% ORR <10% MRD-ve <10% MRD-ve <5-10% MRD-ve <5% P12 1.
Slide 13: Key Questions Being Addressed in BALLI-01 Trial
Key Questions Being Addressed in BALLI-01 Trial Is Cellectis’ manufactured Is Alemtuzumab needed to product superior? optimize response? What is the optimal dose? Which endpoint best reflects benefit? P13
Slide 14: BALLI-01 Study Design
BALLI-01 Study Design Is our internal manufacturing superior? Process 1 vs Process 2 DL1=1×105 cells/kg DL2= 1×106 cells/kg DL2i= 2.5×106 cells/kg DL 3 DL 3 DL3= 5×106 cells/kg DL 2i DL 2i Study What is the design optimal dose? DL 2 DL 2 DL 2 DL 1 FC vs FCA Is alemtuzumab necessary? DL1: Dose Level
Slide 15: Cellectis Manufactured Product (P2) Is Superior to CDMO Product (P1)
Cellectis Manufactured Product (P2) Is Superior to CDMO Product (P1) Overall Response Rate 80 (%) 70 68 60 Higher Percentage (%) 50 32 response 40 28 rates in 30 6 P2 cohort 20 36 10 22 0 P1 (n=18 P2 (n=22) CR/CRi MLFS P15
Slide 16: BALLI-01 Phase 1 Data
R&D Day BALLI-01 Phase 1 Data DRAFT
Slide 17: BALLI-01 Study Design
BALLI-01 Study Design Process 1 vs Process 2 DL1=1×105 cells/kg DL2= 1×106 cells/kg DL2i= 2.5×106 cells/kg DL 3 DL 3 DL3= 5×106 cells/kg DL 2i DL 2i Study design DL 2 DL 2 DL 2 DL 1 FC vs FCA DL1: Dose Level 1; DL2: Dose Level 2; DL2i: Intermedia te Dose L eve l 2; DL 3: Dose L eve l 3; FC: Fluda ra
Slide 18: BALLI-01 Key Inclusion Criteria
BALLI-01 Key Inclusion Criteria Key Inclusion Key Outcomes Exploratory All patients Objectives transplant • Age 15-70 years, • Safety adequate organ • Investigator • UCART22 ineligible at function assessed expansion study entry • ECOG PS ≤1 response • Trafficking, • B-ALL blast CD22 • RP2D of persis
Slide 19: BALLI-01 Demographic and Baseline Characteristics
BALLI 01 | Demographic and Baseline Characteristics DL3 P2 All Subjects (n=12) Age ≤ 50 (n=9) Total (n=40) Age (yrs), median (range) 27 (16-66) 23 (16-45) 27 (16-68) Sex, n (%) Male 5 (41.7) 3 (33.3) 22 (55) Female 7 (58.3) 6 (66.7) 18 (45) ECOG PS, n (%) 0 5 (41.7) 4 (44.4) 14 (35) 1 6 (50) 4 (44.4
Slide 20: Heavily Pretreated Population: Median 4-5 Prior Lines of Therapy
Heavily Pretreated Population: Median 4-5 Prior Lines of Therapy Significant prior treatment with targeted therapies 80% 55% 50% Previously Previously Previously treated treated treated P20
Slide 21: High Response Rates in P2 Cohort
High Response Rates in P2 Cohort Recommended Phase 2 Dose: DL3 Target Phase 2 population: ▪ DL3 ≤ 50 years P21
Slide 22: High Response Rates in P2 Cohort
High Response Rates in P2 Cohort In Target Phase 2 population 80% who achieved CR/CRi were also MRD-ve P22
Slide 23: Deep Responses in P2 Cohort
Deep Responses in P2 Cohort Responder MRD-negative Status (%) 100 CR/CRI ORR 90 80 80 77 75 High Rates 80 73 70 70 of MRD 60 Percentage (%) 60 50 Negativity 50 in Both 40 30 Cohorts 20 10 0 P1 P2 P2 DL3 Target Phase 2 Population n=18 n=22 n=12 n=9 P23 CRi: Complete Remission with incomplete hematolo
Slide 24: Swimmer Plot – Target Phase 2 Population
Swimmer Plot – Target Phase 2 Population Prior (HSCT+Blin+Ino+CAR-T) 9 T 8 T Prior (Blin) 7 T Prior (Blin+Ino+CAR-T) 6 T Prior (Blin) 5 T Prior (Blin+Ino+CAR-T) HSCT Hematopoietic Stem Cell Transplant 4 Prior (HSCT+Blin+Ino+CAR-T) Blin Blinatumomab Ino Inotuzumab CAR-T CAR-T Cell Therapy 3 Prior (In
Slide 25: Improved Survival in Patients Who Responded
Improved Survival in Patients Who Responded Overall Survival over 12 months by Response (P2) Median Overall Survival in Subjects who Achieve MRD- negative CR/CRi 16 14.8 14.8 14 12 10 9.4 Months 8 6 4 2 0 P2 DL3 Target Pivotal 14.8 months Phase 2 Population Median overall survival in subjects who ac
Slide 26: Achieving Transplant: an Important Clinical Outcome
Achieving Transplant: an Important Clinical Outcome Subjects Who Received or Eligible for HSCT (%) 100 90 20 80 100% 70 Received or Percentage (%) 60 Eligible for 50 HSCT 40 80 75 30 In Phase 2 target 55 50 population 20 10 17 0 P2 Overall P2 DL2 (n=6) P2 DL2i (n=4) P2 DL3 (n=12) Target Pivotal (n=2
Slide 27: Improved Survival in Patients Who Achieved Transplant
Improved Survival in Patients Who Achieved Transplant Overall Survival Based on Receiving HSCT (%) All All subjects subjects in in P2 P2 DL3 DL3 received received or or were eligible were eligible for HSCT for HSCT P27
Slide 28: No Impact of Prior Lines of Treatment on Outcome
No Impact No Impact of Prior of Prior Lines Lines ofon of Treatment Treatment Outcome on Outcome Overall Survival Based on Receiving HSCT (P2) P28
Slide 29: High ORR in Patients Who Had Prior Inotuzumab
High ORR in Patients Who Had Prior Inotuzumab ORR in Patients with Prior Exposure to Inotuzumab 100 90 Deep 80 15 responses Percentage (%) 70 8 60 with prior 50 100 40 CD22 71 30 61 targeted 20 10 11 therapy 0 11 (n=9) P1 (n=4) (n=13) P2 (n=11) P2 DL3 (n=5) Target Pivotal Phase 2 Population (n=4) MR
Slide 30: High CR/CRi Rate in Patients Who Had Prior Inotuzumab
High CR/CRi Rate in Patients Who Had Prior Inotuzumab CR/CRi Rates with Prior Inotuzumab Exposure (%) 70 60 Deep 50 responses Percentage (%) 40 with prior 30 60 CD22 20 43 targeted 11 31 10 11 therapy 0 P1 (n=9) P2 (n=13) P2 DL3 (n=7) Target Pivotal Phase 2 population (n=5) MRD-ve CR/CRi MRD+ve CR/C
Slide 31: High ORR in Patients Exposed to Prior Targeted Therapies
High ORR in Patients Exposed to 3 Prior Targeted Therapies: Inotuzumab, Blinatumomab and CD19 CAR-T ORR in Patients with Prior Exposure to 3 Targeted Therapies: Blin, Ino and CD19 CAR-T Deep 100 responses if 90 20 Percentage (%) received all 3 80 70 9 available 60 50 100 targeted 40 80 30 64 therapi
Slide 32: High CR/CRi Rates in Patients Exposed to Prior Targeted Therapies
High CR/CRi Rates in Patients Exposed to 3 Prior Targeted Therapies: Inotuzumab, Blinatumomab and CD19 CAR-T CR/CRi Rate in Patients with Prior Exposure to 3 80 Targeted Therapies: Blin, Ino and CD19 CAR-T 70 Deep 60 responses if received all 3 50 Percentage (%) available 40 targeted 75 therapies 30
Slide 33: Low Incidence of Grade ≥3 CRS and ICANS
Low Incidence of Grade ≥ 3 CRS and ICANS CRS and ICANS: Total Population CRS and ICANS: DL3 (N=18) (N=40) 100 100 90 90 80 5.5 80 70 70 2.5 Percentage (%) 60 Percentage (%) 39 60 32.5 50 50 40 40 12 30 30 12 20 5 20 39 37.5 10 10 10 17 7.5 0 0 CRS ICANS CRS ICANS Grade1 Grade 2 Grade 3 Grade1 Grade
Slide 34: No Current Signal for IEC-HS
No Current Signal for IEC-HS Significant interest in the risk of IEC-HS based on prior CD22 targeting autologous CAR-T ▪ One case observed No in BALLI-01 evidence of IEC-HS CD22 target ▪ Grade 2 HLH Day 5 incidence related ▪ Resolved with Anakinra/Dex effect P34 IEC-HS: Immune Effector Cell–Associat
Slide 35: Lasme-cel | Related SAEs
Lasme-cel | Related SAEs* Preferred Term Grade Dose Level DL3 (n=18) ALL (n=40) 3 DL3 1 (5.5) Cytokine release syndrome 2 (5) 2 DL2 Immune effector cell-associated 3 DL3 2 (11.1) 2 (5) neurotoxicity syndrome Platelet count decreased 4 DL2 1 (2.5) Hydrocephalus 3 DL2 1 (2.5) Sepsis 5 DL2 1 (2.5) Graf
Slide 36: Lasme-cel | Adverse Events of Special Interest (AESI)
Lasme-cel | Adverse Events of Special Interest (AESI) Preferred Term Grade Dose Level DL3 (N=18, %) All (N=40, %) Patients with at least 1 AESI 4 (22.2) 5 (12.5) Cytokine release syndrome 3 DL3 (P2) 1 (5.5) 1 (2.5) Immune effector cell-associated 3 DL3 (P2) 2 (11.1) 2 (5) neurotoxicity syndrome Graf
Slide 37: CLLS52 Related Infections: Grade ≥3
CLLS52 Related Infections: Grade ≥ 3 7/35 (20%) of subjects had infection Grade ≥ 3 considered related to alemtuzumab Phase 2 Risk Mitigation: Enhanced Prophylaxis Related to Related to Related to P1 or P2 Dose Level Preferred Term Grade Alemtuzumab Cyclophosphamide Fludarabine P1 DL3 Oral herpes 3
Slide 38: CMV Reactivation: All Subjects
CMV Reactivation: All Subjects Grade Related to Related to Related to Related to Dose Level P1 or P2 Preferred Term Value UCART Alemtuzumab Cyclophosphamide Fludarabine DL2 P1 Cytomegalovirus infection 2 No YES YES YES Cytomegalovirus infection DL2I P1 2 No NO NO NO reactivation DL2 P2 Cytomegalovir
Slide 39: Data Suggest Alemtuzumab Is Key to Achieving Response
Data Suggest Alemtuzumab Is Key to Achieving Response Patients Who Achieved MRD- Negative Status 60 55% 50 40 Deeper 31% Responses With 30 P2 Alemtuzumab as P Part of 20 2 Lymphodepletion PP1 10 1 0% 0 n=5 n=5 n=13 n=13 n=22 n=22 FC FC FCA FCA FCA FCA P39 FC: Fludarabine and cyclophosphamide ; FCA:
Slide 40: BALLI-01 Transition to Pivotal Phase 2
R&D Day BALLI-01 Transition to Pivotal Phase 2 DRAFT
Slide 41: Clear Registration Path for Lasme-Cel in r/r-ALL
Clear Registration Path for Lasme-Cel in r/r-ALL P41
Slide 42: Study Design: Pivotal Phase 2
Phase Study 2 Pivotal Design: Phase Pivotal 2 2 Phase Interim analysis 1: Interim analysis 2: Primary analysis Overall Dose Optimization 50% pivotal Cohort for BLA Survival Primary Endpoint: CR / CRi, evaluated within 3 months (from Day 28 to Day 84) Age 12-50 years P42
Slide 43: Age Distribution of ALL Target Population
Age Distribution of ALL 8 Target Phase 2 population (Including Pediatric Plan) 7 Potential future target 6 population Incidence per 100,000 5 Current plan includes 4 patients 3 0-50 years old: >70% of total 2 patients 1 0 <1 1-4 5-9 10-14 15-19 20-29 30-39 40-49 50-59 60-69 70-79 80+ Age P43
Slide 44: Recruitment Driven by 75 Planned Study Sites
Recruitment Driven by 75 Planned Study Sites 75 Study centers planned in North America and Europe P44
Slide 45: Multiple Catalysts to 2H 2028
Clear Registration Path to BLA Submission Targeted For 2028: Key Anticipated Milestones Multiple Catalysts to 2H 2028 P45 BLA: Biologics licence application
Slide 46: Lasme-cel Commercial Opportunity
R&D Day Lasme-cel Commercial Opportunity DRAFT
Slide 47: Lasme-cel is a Highly Differentiated Off-the-shelf CAR-T
Lasme-cel is a Highly Differentiated Off-the-shelf CAR-T Lasme-cel Product Overview and Differentiation Potential first-in-class CD22 CAR-T, providing a potent alternative to CD22 CAR CD19-targeting agents Off-the-shelf therapy enables immediate treatment initiation, Allogeneic Therapy significantly
Slide 48: Lasme-cel Can Fill Whitespace In the B-ALL Treatment Paradigm
Lasme-cel Can Fill Whitespace In the B-ALL Treatment Paradigm Select FDA-Approved Therapies in B-ALL Target CD19 CD22 ADC TCE Auto CAR-T Allo CAR-T Lasme-cel Lasme-cel is positioned to be the first CD22 allogeneic CAR-T therapy to market Additional treatments not shown include chemotherapy and TKIs
Slide 49: Chemo and CD19-directed Therapies are Mainstays of B-ALL Treatment
Chemo and CD19-directed Therapies are Mainstays of B-ALL Treatment ALL Treatment Paradigm Induction: Chemo (± TKI1) Initial treatment with chemo ± TKI, with Blincyto Frontline (CD19 TCE) consolidation increasingly used in Consolidation: Blincyto ± Chemo ± TKI 1L following 2024 label expansion 1 Pati
Slide 50: Chemo and CD19-directed Therapies are Mainstays of B-ALL Treatment
Chemo and CD19-directed Therapies are Mainstays of B-ALL Treatment ALL Treatment Paradigm Induction: Chemo (± TKI1) Initial treatment with chemo ± TKI, with Blincyto Frontline (CD19 TCE) consolidation increasingly used in Consolidation: Blincyto ± Chemo ± TKI 1L following 2024 label expansion Often
Slide 51: Chemo and CD19-directed Therapies are Mainstays of B-ALL Treatment
Chemo and CD19-directed Therapies are Mainstays of B-ALL Treatment ALL Treatment Paradigm Induction: Chemo (± TKI1) Initial treatment with chemo ± TKI, with Blincyto Frontline (CD19 TCE) consolidation increasingly used in Consolidation: Blincyto ± Chemo ± TKI 1L following 2024 label expansion Often
Slide 52: Chemo and CD19-directed Therapies are Mainstays of B-ALL Treatment
Chemo and CD19-directed Therapies are Mainstays of B-ALL Treatment ALL Treatment Paradigm Induction: Chemo (± TKI1) Initial treatment with chemo ± TKI, with Blincyto Frontline (CD19 TCE) consolidation increasingly used in Consolidation: Blincyto ± Chemo ± TKI 1L following 2024 label expansion Often
Slide 53: Lasme-cel Potential to Reach Up To ~1.9K Addressable 3L+ Patients
Lasme-cel Has the Potential to Reach Up To ~1.9 K Addressable 3L+ Patients U.S. and EU4+UK 2035E Lasme-cel Addressable Population Incident 1L Treated B-ALL Population (2035E) ~9.2 K Patients (~5.1 K U.S. + ~4.1 K EU4+UK) Note: Values may not multiply exactly due to rounding. Source: Joshi. Clin Ly
Slide 54: Lasme-cel Potential to Reach Up To ~1.9K Addressable 3L+ Patients
Lasme-cel Has the Potential to Reach Up To ~1.9 K Addressable 3L+ Patients U.S. and EU4+UK 2035E Lasme-cel Addressable Population Incident 1L Treated B-ALL Population (2035E) ~9.2 K Patients (~5.1 K U.S. + ~4.1 K EU4+UK) Of the ~9.2 K expected B-ALL patients, ~45% are expected to progress to 2L, ~45
Slide 55: Lasme-cel Potential to Reach Up To ~1.9K Addressable 3L+ Patients
Lasme-cel Has the Potential to Reach Up To ~1.9 K Addressable 3L+ Patients U.S. and EU4+UK 2035E Lasme-cel Addressable Population Incident 1L Treated B-ALL Population (2035E) ~9.2 K Patients (~5.1 K U.S. + ~4.1 K EU4+UK) Of the ~9.2 K expected B-ALL patients, ~45% are expected to progress to 2L, ~45
Slide 56: Lasme-cel Potential to Reach Up To ~1.9K Addressable 3L+ Patients
Lasme-cel Has the Potential to Reach Up To ~1.9 K Addressable 3L+ Patients U.S. and EU4+UK 2035E Lasme-cel Addressable Population Incident 1L Treated B-ALL Population (2035E) ~9.2 K Patients (~5.1 K U.S. + ~4.1 K EU4+UK) Of the ~9.2 K expected B-ALL patients, ~45% are expected to progress to 2L, ~45
Slide 57: Lasme-cel Has the Potential To Capture a Majority of the 3L+ Market
Lasme-cel Has the Potential To Capture a Majority of the 3L+ Market Value Proposition of 3L+ Treatment Options Lasme-cel “MRD negativity is very encouraging compared to what we have in third Alternative target to CD19 Off-the shelf availability line.” – ALL Key Opinion Leader One-time dosing
Slide 58: Lasme-cel Has High Pricing Potential Across the EU4 + UK and U.S.
Lasme-cel Has High Pricing Potential Across the EU4 + UK and U.S. Lasme-cel Ilustrative List Price, If Approved 500 CAR-T Price1 ($ K) Tecartus 400 Lasme-cel 300 Kymriah 200 2025 Avg: ~$365 K 100 0 2020 2025 2030 2035 • Lasme-cel illustrative anchor price triangulated from 2025 averaged EU4 + UK CAR
Slide 59: Lasme-cel Has High Pricing Potential Across the EU4 + UK and U.S.
Lasme-cel Has High Pricing Potential Across the EU4 + UK and U.S. Lasme-cel Ilustrative List Price, If Approved 500 1,000 CAR-T Price1 ($ K) Kymriah CAR-T Price ($ K) Tecartus +5% 400 800 Aucatzyl Lasme-cel 300 Kymriah 600 Lasme-cel 200 2025 Avg: ~$365 K 400 Tecartus 100 200 2025 Avg: ~$515 K 0 0 20
Slide 60: Lasme-cel Could Achieve Up To ~$700 M in Peak Gross Sales
Lasme-cel Could Achieve Up To ~$700 M in Peak Gross Sales (U.S., EU4, UK) Assumption Source / Rationale Addressable Patients (#) ~1.1 K ~840 Represents expected 3L CAR-T eligible patients in 2035 x x • Triangulated using physician-reported preferences and average market share of Preference Share (%)
Slide 61: Peak Sales Could Increase to Up To ~$1.3 B with Label Expansion
Peak Sales Could Increase to Up To ~$1.3 B with Label Expansion ILLUSTRATIVE Allo CAR-T Eligible Patients 2035E Patient Segment Peak Sales 3L+ (Potential First Approval) Current CAR-T Large opportunity in the initial lasme-cel ~$700 M U.S. ~4501 EU ~3502 indication Treated Patients + Expansion to Se
Slide 62: Lasme-cel Can Drive Meaningful Growth of the CAR-T Market In B-ALL
Lasme-cel Can Drive Meaningful Growth of the CAR-T Market In B-ALL First-in-class Immunotherapy Beyond CD19 Lasme-cel Deep Responses with High CR Rates Opportunity and Impressive MRD Negativity Robust Peak Sales Potential (Up To ~$700 M) With Highly Attractive Margins CR: Complete Remission; MRD: Mi
Slide 63: Multiple Catalysts to 2H 2028
Clear Registration Path to BLA Submission Targeted For 2028: Key Anticipated Milestones Multiple Catalysts to 2H 2028 P63
Slide 64: Cellectis Strategic Roadmap
Cellectis Strategic Roadmap Lasme-cel Potential BLA Filing in r/r B-ALL (2028) Eti-cel Potential EoP1 in r/r NHL (2026) Preclinical PoC for In Vivo Gene Therapy (2026) P64 EoP1: End-of-Phase 1 ; PoC: Proof-of-concept
Slide 65: Thank You
Thank You Reach us at: [email protected] Cellectis Paris Cellectis New York Cellectis Raleigh 8, rue de la Croix Jarry 75013 430 East 29th Street 2500 Sumner Boulevard Paris – France New York, NY, 10016 – USA Raleigh, NC, 27616 – USA Cellectis®, TALEN® and our corpora te logo s are reg istered